The FDA has approved a new pediatric heart valve designed to grow with children, which could limit the need for repeated open-heart procedures. Developed by Edwards Lifesciences, the Autus valve features synthetic polymer leaflets rather than animal tissue, marking the first time such material has been used in an FDA-cleared valve. The device starts at 13 millimeters and can be enlarged to 22 millimeters via a balloon catheter, eventually matching the dimensions of an adult valve.
A key study involving 62 children across 12 U.S. medical centers demonstrated the valve’s effectiveness, with all implants successful and blood flow remaining stable after six months. While three patients experienced valve frame fractures and two had leaflet movement issues, no corrective action was required. Two children who outgrew the valve underwent successful expansions without surgery.
The FDA highlighted that conventional valves using animal tissue break down faster in growing children, often necessitating multiple surgeries. The Autus valve’s synthetic construction aims to resolve this challenge. Acting FDA Commissioner Kyle Diamantas described the approval as a major advancement for patients facing limited treatment options.
Read Also: AI to Boost Healthcare Costs Before Cutting Them
Edwards Lifesciences acquired the technology through its $128.9 million purchase of Autus Valve Technologies in February, with potential additional payments tied to performance milestones. An earlier option agreement had cost $11.5 million. This approval strengthens Edwards’ existing pediatric heart disease offerings, which already include the Sapien 3 valve and the Alterra Adaptive Prestent.
The valve earned FDA breakthrough device designation, expediting its review as an innovative treatment. It also represents the first pediatric approval under the FDA’s total product life cycle advisory program, a framework intended to simplify the development of new medical devices.
Participants in the trial will be tracked for 10 years, with initial one-year results indicating the synthetic leaflets maintain performance over time. The FDA stressed that the valve may reduce the likelihood of children requiring multiple surgeries, a decision doctors often struggle to time correctly to avoid long-term complications.
